Pemigatinib for the treatment of metastatic or unresctable colorectal cancer

What is the Purpose of this Study?

If you choose to join this study, you will:
-Take the study drug, pemigatinib, by mouth once per day
-Return to the clinic every 3 weeks so we can monitor your health
-Give blood and urine for testing
-Get CT or MRI scans every 9 weeks

You may be on the study drug for up to 2 years.
What is the Condition Being Studied?
Colorectal Cancer

Who Can Participate in this Study?

Adults with colorectal cancer that:

-Is metastatic or unresectable; and

-Contains alterations in the genes FGFR1, FGFR2, or FGFR3

Additionally, eligible participants must have failed prior standard-of-care therapy or not be able to tolerate it.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to see if the study drug, pemigatinib, is safe and effective for fighting a specific type of colorectal cancer.

Study Details

Full Title
[ACCRU-GI-1701] A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients with Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Principal Investigator

Protocol Number
IRB:
PRO00105296

NCT:
NCT04096417
ClinicalTrials.gov
View on ClinicalTrials.gov